These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 15355570)

  • 1. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases.
    Munns CF; Rauch F; Ward L; Glorieux FH
    J Bone Miner Res; 2004 Oct; 19(10):1742-5. PubMed ID: 15355570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA; Ford L; McClintock C; Peacock M
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
    Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
    Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two doses of pamidronate in infants with osteogenesis imperfecta.
    Senthilnathan S; Walker E; Bishop NJ
    Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS; Glorieux FH; Rauch F
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.
    Munns CF; Rauch F; Travers R; Glorieux FH
    J Bone Miner Res; 2005 Jul; 20(7):1235-43. PubMed ID: 15940378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
    Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
    Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.
    Chan B; Zacharin M
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2017-20. PubMed ID: 16551739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
    Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
    J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
    Rauch F; Plotkin H; Zeitlin L; Glorieux FH
    J Bone Miner Res; 2003 Apr; 18(4):610-4. PubMed ID: 12674321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
    Bajpai A; Kabra M; Gupta N; Sharda S; Ghosh M
    J Pediatr Orthop; 2007 Mar; 27(2):225-7. PubMed ID: 17314651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
    Rauch F; Glorieux FH
    Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.